Pegylated interferon-2a invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation

Andrea S. Henden, Antiopi Varelias, Justine Leach, Elise Sturgeon, Judy Avery, Jessica Kelly, Stuart Olver, Luke Samson, Gunter Hartel, Simon Durrant, Jason Butler, Anthony J. Morton, Ashish Misra, Siok-Keen Tey, Elango Subramoniapillai, Cameron Curley, Glen Kennedy,* and Geoffrey R. Hill* Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; Bone Marrow Transplantation Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Herston, QLD, Australia; Statistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and Division of Medical Oncology, The University of Washington, Seattle, WA